Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05249114 · ClinicalTrials.gov registry record · Phase 1
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
A Phase 1 study of Neuroendocrine Tumors, sponsored by Providence Health & Services.
- Active
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT05249114 is a Phase 1 study of Neuroendocrine Tumors that is active but no longer recruiting, run by Providence Health & Services. The registered enrollment target is 6 participants, below the 180-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05249114, a Phase 1 study of Neuroendocrine Tumors, is active but no longer recruiting, sponsored by Providence Health & Services.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
The phase I objective of this study is to establish the maximal tolerated dose (MTD) of cabozantinib in 20 mg, 40 mg and 60 mg dose escalation cohorts in combination with Lu-177 dotatate at a standard dose of 7.4 GBq in four (4) 8-week cycles followed by continuation cabozantinib.
Conditions Studied
Interventions
- DRUG Cabozantinib
- DRUG Lu-177
Study Locations (1)
Oregon
- Providence Portland Cancer Institute - Franz Clinic - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-12-28 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05249114
The ClinicalTrials.gov registry entry for NCT05249114 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 180-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (97% lower). The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 2 interventions - of which Cabozantinib is the first listed.
NCT05249114 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT05249114 about?
NCT05249114 is a clinical study titled "Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors". The phase I objective of this study is to establish the maximal tolerated dose (MTD) of cabozantinib in 20 mg, 40 mg and 60 mg dose escalation cohorts in combination with Lu-177 dotatate at a standard dose of 7.4 GBq in four (4) 8-week cycles followed by continuation cabozantinib.
What is the current status of trial NCT05249114?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2022-12-28. Estimated completion is 2026-12.
What conditions does trial NCT05249114 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors.
What interventions are being tested in trial NCT05249114?
The interventions under investigation include: Cabozantinib (DRUG), Lu-177 (DRUG).
Who is sponsoring clinical trial NCT05249114?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05249114 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
RECRUITING · Phase 1
-
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
RECRUITING · Phase 1
-
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.